20092 ⎘
Medicinal preparations characterised by special physical form; Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles; Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
LINACLOTIDE COMPOSITIONS
#302Treatment of Constipation-Predominant Irritable Bowel Syndrome
#303SOLID MOLECULAR DISPERSION OF FESOTERODINE HYDROGEN FUMARATE AND POLYMERIC BINDER
#304Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
#305Controlled extended release pregabalin
#306Sustained-release formulations of topiramate
#307PALATABLE COMPOSITIONS INCLUDING SODIUM PHENYLBUTYRATE AND USES THEREOF
#308Formulation comprising particles containing a water-swellable or water-soluble polymeric component and a lipid component
#309Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
#310COMPOSITIONS AND METHODS FOR THE TREATMENT AND PROPHYLAXIS OF SURGICAL SITE INFECTIONS
#311Pharmaceutical composition of rosuvastatin calcium
#312APPLICATION OF ANDROGRAPHOLIDE IN THE PREPARATION OF A PHARMACEUTICAL FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE, ANDROGRAPHOLIDE ENTERIC TARGETING MICROPELLET, AND METHOD FOR PREPARATION THEREOF
#313APPLICATION OF ANDROGRAPHOLIDE IN THE PREPARATION OF A PHARMACEUTICAL FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE, ANDROGRAPHOLIDE ENTERIC TARGETING MICROPELLET, AND METHOD FOR PREPARATION THEREOF
#314Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
#315Formulations of guanylate cyclase C agonists and methods of use
#316Formulations of guanylate cyclase C agonists and methods of use
#317MEDICAMENT-CONTAINING HOLLOW PARTICLE
#318IMMEDIATE RELEASE DOSAGE FORMS THAT DETER ABUSE BY ORAL INGESTION OF MULTIPLE DOSAGE UNITS
#319FOOD CONTAINING PROLACTIN
#320Nanoparticles containing azolium and N-heterocyclic carbene compounds and use thereof
#321Albumin nanoparticles to augment stem cell function in vivo
#322Metoprolol sustained-release composition and preparation method thereof
#323Timed, pulsatile release systems
#324Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
#325Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
#326Naltrexone hydrochloride compositions
#327Compositions for treatment of attention deficit hyperactivity disorder
#328Pharmaceutical formulations
#329Pharmaceutical combinations of dabigatran and proton pump inhibitors
#330Composition of analgesic bioadhesive healing microspheres
#331Sustained-release formulations of topiramate
#332Sustained-release formulations of topiramate
#333Pharmaceutical compositions of sitagliptin
#334Orally disintegrating compositions
#335Pharmaceutical or nutraceutical composition with sustained release characteristic and with resistance against the influence of ethanol
#336Drinking water formulation and method and article relating to same
#337Oral liquid compositions of guanfacine
#338Extended release liquid compositions of guanfacine
#339Method of drug formulation
#340Curcumin coated magnetite nanoparticles for biomedical applications
#341Formulations of 6-mercaptopurine
#342Therapeutic agents and delivery with microspheres
#343Abuse resistant pharmaceutical compositions
#344Formulations containing nalbuphine and uses thereof
#345Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant agent
#346Treating pain in patients with hepatic impairment
#347Method and compositions for dissolving or solubilizing therapeutic agents
#348Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14,-diol
#349Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
#350Sustained delivery of therapeutic agents to an eye compartment
#351Multifunctional metal nanoparticles having a polydopamine-based surface and methods of making and using the same
#35217-hydroxyprogesterone ester-containing oral compositions and related methods
#353ANTIMICROBIAL COMPOSITION COMPRISING PYROGENIC SILICA AND SERRATHOPEPTIDASE AND USES THEREOF
#354Compositions for treatment of attention deficit hyperactivity disorder
#355THE SYNTHESIS OF CORE-SHELL METAL-SEMICONDUCTOR NANOMATERIALS
#356Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof
#357Pharmaceutical formulation containing thienotriazolodiazepine compounds
#358Compositions and methods of using modified release solabegron for lower urinary tract symptoms
#359Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
#360Tunable anti-microbial loaded hydrogels
#361COATED PARTICLES AND COMPOSITIONS COMPRISING SAME
#362Methods and compositions particularly for treatment of attention deficit disorder
#363Timed, pulsatile release systems
#364METHOD AND PROCESS FOR THE PRODUCTION OF MULTI-COATED RECOGNITIVE AND RELEASING SYSTEMS
#365Pulsed release phenylephrine dosage forms
#366Abuse resistant pharmaceutical compositions
#367Abuse resistant pharmaceutical compositions
#368Secnidazole for use in the treatment of bacterial vaginosis
#369Gene optimized hantaan virus M segment DNA vaccine for hemorrhagic fever with renal syndrome
#370Timed, pulsatile release systems
#371Nutritional and medicinal oral composition for veterinary use
#372METHOD OF REDUCING SOMNOLENCE IN PATIENTS TREATED WITH TIZANIDINE
#373NANOPARTICLES, METHODS OF PREPARATION, AND USES THEREOF
#374Sustained-release formulations of topiramate
#375Pharmaceutical composition of doxycycline with reduced food effect
#376Formulations of guanylate cyclase C agonists and methods of use
#377ORAL PHARMACEUTICAL COMPOSITION COMPRISING DABIGATRAN ETEXILATE
#378Increasing drug affinity for crystalline microparticle surfaces
#379Process for preparing products comprising stabilised actives and compositions comprising same
#380IN VIVO PHOTOACOUSTIC AND PHOTOTHERMAL NANO-THERANOSTICS OF BIOFILMS
#381Treating pain in patients with hepatic impairment
#382Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases
#38317-hydroxyprogesterone ester-containing oral compositions and related methods
#384Rehydratable pharmaceutical product
#385Solid ganaxolone compositions and methods for the making and use thereof
#386COMPOSITION FOR IMMEDIATE AND EXTENDED RELEASE
#387Antimicrobial composition comprising pyrogenic silica and serrathiopeptidase and uses thereof
#388Pharmaceutical core-shell composite powder and processes for making the same
#389Formulations of 6-mercaptopurine
#390Cell Transport Compositions and Uses Thereof
#391New Treatment
#392MODIFIED AND IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE
#393Escalating Dosing Regimen for Effecting Weight Loss and Treating Obesity
#394Method for preparing a bone protein preparation and a bone protein preparation
#395GASTRO-RETENTIVE DRUG DELIVERY SYSTEM
#396Cross-linked polymer particles
#397Tamper-resistant oral opioid agonist formulations
#39817-Hydroxyprogesterone ester containing oral compositions and related methods
#399FORMULATIONS FOR A TIGHT JUNCTION EFFECTOR
#400FOOD CONTAINING PROLACTIN
#401Compositions for treatment of attention deficit hyperactivity disorder
#402Immediate release abuse-deterrent granulated dosage forms
#403Immediate release abuse-deterrent granulated dosage forms
#404Immediate Release Abuse-Deterrent Granulated Dosage Forms
#405Process for obtaining a modafinil-based pharmaceutical composition, resulting pharmaceutical composition and use thereof
#406Controlled dose drug delivery system
#407Abuse resistant forms of immediate release oxymorphone, method of use and method of making
#408Abuse resistant forms of extended release hydrocodone, method of use and method of making
#409Nitazoxadine composition and process to prepare same
#410Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
#411ABUSE RESISTANT FORMS OF EXTENDED RELEASE HYDROMORPHONE, METHOD OF USE AND METHOD OF MAKING
#412ABUSE RESISTANT FORMS OF IMMEDIATE RELEASE HYDROCODONE, METHOD OF USE AND METHOD OF MAKING
#413Abuse resistant forms of extended release oxymorphone, method of use and method of making
#414Abuse resistant forms of immediate release hydromorphone, method of use and method of making
#415Joint product comprising synephrine and topiramate
#416Treating pain in patients with hepatic impairment
#417ABUSE RESISTANT FORMS OF IMMEDIATE RELEASE OXYCODONE, METHOD OF USE AND METHOD OF MAKING
#418Sustained delivery of therapeutic agents to an eye compartment
#419Tamper resistant immediate release formulations
#420Aptamer bioconjugate drug delivery device
#421Testosterone undecanoate compositions
#422Escalating dosing regimen for effecting weight loss and treating obesity
#423Linaclotide compositions
#424Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
#425Nanoparticulate formulation comprising a TRPA1 antagonist
#426Abuse resistant forms of extended release morphine, method of use and method of making
#427Controlled release oral dosage form comprising oxycodone
#42817-hydroxyprogesterone ester containing oral compositions and related methods
#429Curcumin coated magnetite nanoparticles for biomedical applications
#430MULTIPLE UNIT PELLET TABLET FORMULATION COMPRISING AN OPIOID
#431Compositions for treatment of heart failure in dogs
#432SUSTAINED-RELEASE TOPIRAMATE FORMULATIONS
#433Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
#434Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
#435Optimal colon targeting technology
#436Crosslinked gelatin support and support for controlled release of physiologically active substance using the same
#437Agent for evading immune response
#438Formulation for the controlled release of one or several substances in the digestive tract of a mammal
#439Pharmaceutical Composition of Rosuvastatin Calcium
#440TAMPER RESISTANT IMMEDIATE RELEASE FORMULATIONS
#44117-hydroxyprogesterone ester containing oral compositions and related methods
#442PHARMACEUTICAL FORMULATION OF NANONIZED FENOFIBRATE
#443Abuse resistant forms of extended release morphine, method of use and method of making
#444Abuse resistant forms of extended release morphine, method of use and method of making
#445Taste masked pharmaceutical composition
#446Stable solid preparations
#447Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol
#448Formulations of 6-mercaptopurine
#449Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant agent
#450Solid ganaxolone compositions and methods for the making and use thereof
#451Risperidone microparticles formed by sublimation
#452Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases
#453MICROPELLET COMPOSITIONS COMPRISING PANCREATIN CONTAINING DIGESTIVE ENZYME MIXTURE
#454Coating method
#455Method for producing solid formulations comprising immunoglobulin single variable domains
#456Powderous vitamin E formulations
#457MASS PRODUCTION OF READY-TO-USE SUSPENSIONS OF FIBRINOGEN-COATED ALBUMIN SPHERES FOR THE TREATMENT OF THROMBOCYTOPENIC PATIENTS
#458Aptamer bioconjugate drug delivery device
#459Chemoembolization composition comprising anti-angiogenic agents
#460Ternary mixture formulations
#461Liquid ganaxolone formulations and methods for the making and use thereof
#462Solid molecular dispersion of fesoterodine hydrogen fumarate and polymeric binder
#463ORAL PHARMACEUTICAL COMPOSITIONS OF NEBIVOLOL AND PROCESS FOR THEIR PREPARATION
#464Abuse-resistant oral dosage forms and method of use thereof
#465Cross-linked polymer particles
#466Oral Pharmaceutical Composition of Duloxetine
#467Sustained-release pellets containing tacrolimus as an active ingredient
#468Non-abusable pharmaceutical composition comprising opioids
#469NANOVECTORS FOR TARGETED GENE SILENCING AND CYTOTOXIC EFFECT IN CANCER CELLS
#470Pharmaceutical compositions comprising hydromorphone and naloxone
#471Stable beadlets of lipophilic nutrients
#472Methods and compositions for delivering peptides
#473Beclomethasone dipropionate compositions in modified-release gastro-resistant microspheres and process for obtaining them
#474Method for treating celiac disease
#475Solid Dosage Forms of Antipsychotics
#476Temperature dependent activation of catalytic nucleic acids for controlled active substance release
#477CONTROLLED RELEASE FORMULATION FOR TREATING SLEEP DISORDERS
#478Gastroretentive Solid Oral Dosage Forms with Swellable Hydrophilic Polymer
#479INHIBITORS FOR TREATING AND PREVENTING HEART FAILURE IN FELINES
#48017-hydroxyprogesterone ester-containing oral compositions and related methods
#481Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
#482Controlled release pharmaceutical compositions of tapentadol
#483GASTRIC ACID SECRETION INHIBITING COMPOSITION
#484MODIFIED AND IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE
#485Drinking water formulation and method and article relating to same
#486Utilization of dialkylfumarates
#487MULTI-PARTICULATE PHARMACEUTICAL FORMULATION FOR COLON ABSORPTION
#488Sustained delivery of therapeutic agents to an eye compartment
#489Pharmaceutical composition
#490Sustained-release formulations of topiramate
#491Pharmaceutical or neutraceutical formulation
#492THERAPEUTIC REGIMENS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS
#493Tamper-resistant oral opioid agonist formulations
#494ORGANIC COMPOUNDS
#495METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED SAFETY PROFILE OVER CONVENTIONAL WARFARIN THERAPY
#496METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED EFFICACY OVER CONVENTIONAL WARFARIN THERAPY
#497BARRIER COMPOSITION
#498Preformulation for tabletting natural mixtures of conjugated estrogens
#499Multifunctional metal nanoparticles having a polydopamine-based surface and methods of making and using the same
#500Formulations of guanylate cyclase C agonists and methods of use
#501Process for preparing products comprising stabilised actives and compositions comprising same
#502PHARMACEUTICAL COMPOSITIONS WITH TETRABENAZINE
#503Formulations of 6-mercaptopurine
#504Compositions controlling pH range of release and/or release rate
#505Pharmaceutical compositions for the deterrence and/or prevention of abuse
#506PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF OVERACTIVE BLADDER
#507MODIFIED AND IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE
#508Pharmaceutical formulation containing an opioid agonist, opioid antagonist and irritant agent
#509COMPOSITIONS OF 5-HT3 ANTAGONISTS AND DOPAMINE D2 ANTAGONISTS FOR TREATMENT OF DOPAMINE-ASSOCIATED CHRONIC CONDITIONS
#510ORAL DOSAGE FORM FOR MODIFIED RELEASE COMPRISING A JAK3 INHIBITOR
#511Pharmaceutical Compositions
#512Emulsion Compositions
#513Pellets coated with coatings containing active substances
#514DRUG COATING PROVIDING HIGH DRUG LOADING AND METHODS FOR PROVIDING THE SAME
#515Pharmaceutical formulations to prevent the misuse of medicinal drugs
#516Abuse resistant oral opioid formulations
#517Abuse resistant forms of immediate release oxycodone, method of use and method of making
#518TESTOSTERONE UNDECANOATE COMPOSITIONS
#519Coating method
#520APTAMER BIOCONJUGATE DRUG DELIVERY DEVICE
#521Timed, pulsatile release systems
#522Gastric Acid Secretion Inhibiting Composition
#523Stable tablet containing 4,5-epoxymorphinan derivative
#524Immunogenic compositions containing phospholipid
#525METHOD OF INCREASING THE EXTENT OF ABSORPTION OF TIZANIDINE
#526MEDICINE FOR TREATMENT OF A CARCINOMA
#527CHRONOTHERAPEUTIC COMPOSITIONS AND METHODS OF THEIR USE
#528FOOD CONTAINING PROLACTIN
#529Branched Polyesters Based On Citric Acid, Their Preparation And Use
#530SOLID RETIGABINE IN NON-CRYSTALLINE FORM
#531Liquid ganaxolone formulations and methods for the making and use thereof
#532Method for treating hyperglycemia
#533Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration
#534Nano-carrier, complex of anticancer drug and nano-carrier, pharmaceutical composition thereof, method for manufacturing the complex, and method for treating cancer by using the pharmaceutical composition
#535METHOD OF REDUCING SOMNOLENCE IN PATIENTS TREATED WITH TIZANIDINE
#536AMORPHOUS AMBRISENTAN
#537Drug Delivery Catheters That Attach to Tissue and Methods for Their Use
#538Drug coating providing high drug loading and methods for providing the same
#539SOLID COMPOSITION CONTAINING THE INGREDIENT RASAGILINE
#540CONTROLLED RELEASE COMPOSITIONS COMPRISING ANTI-CHOLINERGIC DRUGS
#541COMPOSITION FOR MANUFACTURING ORALLY DISINTEGRATING DOSAGE FORM TO PROTECT COATING LAYER OF ACTIVE SUBSTANCE
#542PHARMACEUTICAL FORMULATION OF NANONISED FENOFIBRATE
#543INFLAMMATION TARGETING PARTICLES
#544TASTE MASKED DOSAGE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT OF ESCITALOPRAM
#545Utilization of dialkylfumarates
#546METHOD OF TREATING CORONARY ARTERIES WITH PERIVASCULAR DELIVERY OF THERAPEUTIC AGENTS
#547Sustained-release formulations of topiramate
#548Sustained-release formulations of topiramate
#549METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED EFFICACY OVER CONVENTIONAL WARFARIN THERAPY
#550Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
#551METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED EFFICACY OVER CONVENTIONAL WARFARIN THERAPY
#552Pharmaceutical formulations
#553PULSED-RELEASE SILDENAFIL COMPOSITION AND METHOD FOR PREPARING SAID COMPOSITION
#554Dosage Forms
#555Therapeutic calcium phosphate particles and methods of manufacture and use
#556Solid ganaxolone formulations and methods for the making and use thereof
#557COMPOSITIONS AND METHODS FOR TREATING CHRONIC RESPIRATORY INFLAMMATION
#558EMERGENCY INTERVENTIONS OF ACTIVE CHARCOAL WITH DABIGATRAN ETEXILATE OVERDOSING
#559Method Of Treating Attention Deficit Disorders With D-Threo Methylphenidate
#560Anaplerotic Therapy for Alzheimer's Disease and the Aging Brain
#561PHARMACEUTICAL COMPOSITION CONTAINING SURFACE-COATED MICROPARTICLES
#562THERAPEUTIC REGIMENS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS
#563Pharmaceutical compositions configured to deter dosage form splitting
#564GASTRORETENTIVE DRUG DELIVERY SYSTEM, PREPARATION METHOD AND USE THEREOF
#565Extended release venlafaxine formulation
#566PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS
#567Abuse resistant drugs, method of use and method of making
#568Abuse resistant forms of extended release morphine, method of use and method of making
#569Pharmaceutical composition containing fenofibrate and method for the preparation thereof
#570Abuse resistant forms of extended release morphine with oxycodone, method of use and method of making
#571Abuse resistant forms of extended release hydrocodone, method of use and method of making
#572Abuse resistant forms of extended release oxymorphone, method of use and method of making
#573Abuse resistant forms of extended release oxycodone, method of use, and method of making
#574Abuse resistant forms of extended release hydromorphone, method of use and method of making
#575Pharmaceutical Compositions of Atorvastatin
#576Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases
#577Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
#578PHARMACEUTICAL PREPARATION CONTAINING NON-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-2 RECEPTOR BLOCKER
#579Pharmaceutical composition containing water soluble drug
#580COMPOSITIONS OF 5-HT3 ANTAGONISTS AND DOPAMINE D2 ANTAGONISTS FOR TREATMENT OF DOPAMINE-ASSOCIATED CHRONIC CONDITIONS
#581Methods and compositions for delivering peptides
#582Tamper-resistant oral opioid agonist formulations
#583Delivery System for Drug and Cell Therapy
#584Swellable and degradable microspheres
#585Anti-misuse solid oral pharmaceutical form provided with a specific modified release profile
#586Abuse resistant drugs, method of use and method of making
#587NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING CYCLOSPORINE
#588METHOD FOR KILLING CELLS USING PHOTOCATALYTIC TITANIUM DIOXIDE PARTICLES
#589ORAL GALENIC FORMULATION INCLUDING KETOROLAC AND B-COMPLEX VITAMINS, IN WHICH VITAMIN B6 IS IN AN OUTER LAYER SEPARATED FROM THE REST OF THE ACTIVE PRINCIPLES
#590Antidepressant Oral Pharmaceutical Compositions
#591COMPOSITIONS OF 5-HT3 ANTAGONISTS AND DOPAMINE D2 ANTAGONISTS FOR TREATMENT OF DOPAMINE-ASSOCIATED CHRONIC CONDITIONS
#592FORMULATIONS OF FLIBANSERIN
#593STABLE BENZIMIDAZOLE FORMULATION
#594Stable solid preparations
#595SOLUBILITY-ENHANCED FORMS OF APREPITANT AND PHARMACEUTICAL COMPOSITIONS THEREOF
#596PHARMACEUTICAL COMPOSITIONS COMPRISING GRANULES OF PURIFIED MICROBIAL LIPASE AND METHODS FOR PREVENTING OR TREATING DIGESTIVE DISORDERS
#597Device and method for preparing microparticles
#598Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
#599Abuse resistant oral opioid formulations
#600FORMULATION AND PROCESS FOR DRUG LOADED CORES